EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Evotec SE
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 8, 2026
$1.42+0.04 (+2.90%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2018 to 2024
Gross margin
14.4%−15.4 pts over 5 years
Operating margin
-17.9%−31.9 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +2.0% | +8.8% | +12.3% | – | |
| Gross profit | -34.4% | -8.8% | -2.9% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | – | |
| Return on assets | – | – | – | |
| Current ratio | – | – | 1.98 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | 8.4× | – | |
| Inventory turnover | – | – | 22.0× | |
| Capex to revenue | – | 7.0% | 14.7% | |
| Diluted shares | – | 150M | 177M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Evotec generated €431.79M from operations and spent €730.16M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€431.79M
Used
€730.16M
Capital expenditure€730.16M100%Dividends€00%Share buybacks€00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-23.4%
×Asset turnover0.33×
×Equity multiplier1.75×
=Return on equity, FY2022-13.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -23.4% | 0.33× | 1.75× | -13.7% |
| FY2021 | 34.9% | 0.33× | 1.76× | 20.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
3of 5 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero€18.22M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income€18.22M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.94 → 1.98
- No dilutionShare count did not rise177M → 177M
- Gross margin improvedGross margin up on the prior year22.40% → 14.41%
- More efficientAsset turnover rose0.35 → 0.35